POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New way to deliver chemo shows promise for stomach cancer patients
Disease control OngoingThis early-phase study is testing a chemotherapy drug called paclitaxel, given directly into the abdomen, for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The main goal is to find the safest dose and understand side effects…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:02 UTC
-
Immunotherapy plus chemoradiation shows promise for Hard-to-Treat stomach cancer
Disease control OngoingThis early-phase trial tested a combination of the immunotherapy drug pembrolizumab with chemotherapy and radiation in 16 people whose gastroesophageal cancer could not be removed by surgery. The goal was to see if the treatment could shrink or eliminate the cancer. The study is …
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC